Ascentage Pharma Group International - American Depository Shares (NQ:AAPG)

14.61 +0.01 (+0.03%)

Delayed Quote Updated: 3:57 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ascentage Pharma Group International - American Depository Shares

< Previous 1 2 Next >

Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin

April 23, 2025

From ASCENTAGE PHARMA GROUP INTERNATIONAL

Via GlobeNewswire

Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines

April 21, 2025

From ASCENTAGE PHARMA GROUP INTERNATIONAL

Via GlobeNewswire

Argan Posts Upbeat Results, Joins KULR Technology, Abacus Global Management, W. R. Berkley And Other Big Stocks Moving Higher On Friday ↗

March 28, 2025

Via Benzinga

Chinese Biotech Ascentage Pharma's Valuation Driven By Late-Stage De-Risked Assets: JPMorgan ↗

March 27, 2025

JP Morgan sees strong growth for Ascentage Pharma, citing its late-stage cancer drugs. The biotech's 2024 sales surged 342% YoY, driven by a Takeda payment.

Via Benzinga

Ascentage Pharma Reports Full Year 2024 Unaudited Financial Results and Business Updates

March 27, 2025

From ASCENTAGE PHARMA GROUP INTERNATIONAL

Via GlobeNewswire

Earnings Scheduled For March 27, 2025 ↗

March 27, 2025

Via Benzinga

Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025

March 25, 2025

From ASCENTAGE PHARMA GROUP INTERNATIONAL

Via GlobeNewswire

Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025

March 12, 2025

From ASCENTAGE PHARMA GROUP INTERNATIONAL

Via GlobeNewswire

IPO Momentum Builds In 2025: Diginex, CTRL Group, And Others Post Strong Gains ↗

March 10, 2025

US IPO activity saw a meaningful recovery in 2024, with 38% more IPOs and 48% higher proceeds. 2025 may bring even more growth as 36 IPOs have already been priced this year, including Diginex's 600%...

Via Benzinga

Topics Initial Public Offering

Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

March 05, 2025

From ASCENTAGE PHARMA GROUP INTERNATIONAL

Via GlobeNewswire

Ascentage Pharma Announces Partial Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares

February 07, 2025

From ASCENTAGE PHARMA GROUP INTERNATIONAL

Via GlobeNewswire

Ascentage Pharma Announces Closing of U.S. Initial Public Offering

January 28, 2025

From ASCENTAGE PHARMA GROUP INTERNATIONAL

Via GlobeNewswire

< Previous 1 2 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.